Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know originally appeared on Parade.
From morning coffee to vitamins, there are plenty of must-have's that help set up a successful daily routine. In fact, according to Johns Hopkins Medicine, a whopping 50% of American adults take a multivitamin, vitamin or mineral supplement regularly.
If you happen to be part of that group of consistent vitamin takers though, you'll want to double check your medicine cabinet. Because one lot of B12 vitamins is being voluntarily recalled by Vita Warehouse Corp thanks to the potential presence of undeclared peanuts.
🍳 SIGN UP to get delicious recipes, handy kitchen hacks & fun food news in our daily Pop Kitchen newsletter 🍳
Considering these Welby, Berkley Jensen and VitaGlobe vitamins are also sold by some of the most popular retailers like ALDI and Amazon, there's a good chance shoppers may unknowingly have a bottle.
According to a company announcement shared by the U.S. Food and Drug Administration, this recall affects one lot of Aldi Welby B12 Energy Support gummies, Berkely Jensen B12 Vitamin gummies and Vitamin B12 Extra Strength gummies. The FDA warns that 'people with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions,' if they take these vitamins.Fortunately, no illnesses or allergic reactions have been reported so far. The undeclared peanuts were actually discovered by ALDI. After conducting routine testing per its standard protocol, one of the tests 'indicated a potential presence of a peanut allergen.'
While internal testing done by Vita Warehouse Corp. 'verified the absence of peanuts," the recall was issued out of caution.
So, how do you know for sure if you have one of the affected vitamins? There are a few key ways.
First, these were sold nationwide at ALDI and BJ's in-store. They were also sold online on ALDI's, BJ's and VitaGlobe's websites and on Amazon.
Additionally, each product will have an expiration date of October 2026. The company says that each of the affected vitamins have the following UPC codes and Lot numbers.
Aldi Welby: clear bottle with white cap, using green, red, and white labeling. UPC Code: 4099100290868 Lot #: 248046601*
Berkeley Jensen: clear bottle with white cap, using red and pink labeling. UPC Code: 888670132487 Lot #: 248046601*
VitaGlobe: clear bottle with white cap, using white and red labeling. UPC Code: 850005214670 Lot #: 248046601*
The Lot codes and expiration dates can all be found printed on the bottom of each bottle.
The FDA urges consumers who have a peanut allergy to return or throw away any affected vitamins ASAP. Customers who do return them can expect a full refund from the original store of purchase.
Those with further questions can contact Vita Warehouse at 1-855-214-0100 Monday through Friday from 7:30 am to 4 pm ET.Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know first appeared on Parade on Jun 18, 2025
This story was originally reported by Parade on Jun 18, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
30 minutes ago
- CNN
Can Weight Loss Drugs and Body Positivity Coexist? - The Assignment with Audie Cornish - Podcast on CNN Audio
Can Weight Loss Drugs and Body Positivity Coexist? The Assignment with Audie Cornish 34 mins Just a few years ago, 'body positivity' was everywhere. Then came Ozempic. Audie talks with Virginia Sole-Smith, who spent the past decade writing about 'diet culture.' She weighs in on the future of the body positivity in an Ozempic world, and whether the movement and the revolutionary new class of weight loss drugs can coexist. Virginia Sole Smith's book is called ' Fat Talk: Parenting in the Age of Diet Culture. '
Medscape
31 minutes ago
- Medscape
Wait Times to See Physicians Continue to Climb
Your patient has waited 4 weeks for a 15-minute visit, and you're double-booked and distracted. As physician shortages collide with rising demand, wait times have increased, and appointment delays are the norm, not the exception. Patients are frustrated, and physicians are overwhelmed. In fact, according to a new survey conducted by AMN Healthcare, the average physician appointment wait time in 15 major metropolitan areas has increased by 19% since the survey was last conducted in 2022 and by 48% since it was first conducted in 2004. This translates to patients waiting 31 days on average to book time with a healthcare provider, up from 26 days in 2022 and 21 days in 2004. Medscape continually surveys physicians and other medical professionals about key practice challenges and current issues, creating high-impact analyses. For example, Medscape's Artificial Intelligence (AI) Adoption in Healthcare Report 2024 found that Just 18% of physician offices use AI to create staff schedules, yet 30% predict they'll use AI for this in the future. 19% of physician offices use AI for patient census predictions, yet 40% predict they'll use AI for this in the future. One big surprise about the survey is that appointment wait times weren't even longer, Jeff Decker, president of AMN's physician and leadership solutions division, told Medscape Medical News , adding that in Boston, wait times were the longest (65 days), while Atlanta had the shortest wait times (12 days). 'Anecdotally, we've heard of physician appointment wait times that commonly extend 2 or 3 months or more rather than a few weeks or 1 month,' Decker said. 'We think this may be a result of medical practice consolidation, where more physicians are part of large medical groups than has been the case in the past.' In addition, wait times can vary based on whether (or not) the physician accepts Medicare or Medicaid and tend to be even longer when new patients book an appointment with a specialist. The survey found there was a 42-day wait for obstetricians and gynecologists (ob/gyns), a 40-day wait for gastroenterologists, and a 36.5-day wait for dermatologists, something Dara Spearman, MD, a board-certified dermatologist in private practice in Fort Wayne, Indiana, said sounds accurate. 'There are fewer than 10 dermatologists in Fort Wayne, so this creates quite a backlog,' she said. 'Because dermatologists can treat over 3000 diseases, I'm trying to triage a bit and see if we can overlap with other specialties, like having pediatricians or primary care start treatments for a patient with acne, to leave room for patients who need to see us immediately.' Appointment times for serious cases, such as the skin cancers she sees among her farmer patient population, are Spearman's greatest priority. 'When you're talking about melanoma, time is of the essence,' she said. 'Patients have to get in quickly to get it recognized, and the earlier you get it out, the less likely it is to spread. That's why I use the Secure Chat feature on Epic. This way, when primary care reaches out about something they're worried about, I can get that patient in as fast as possible.' Like Spearman, physicians around the country are coming up with other unique solutions to make sure they can get patients into the office as quickly as their schedules will allow. For one, partnering with other professionals can open up patient appointment slots, and many medical practices today, both in primary care and in specialty areas, are using advanced practice professionals to do just that. 'Medical practices are using locum tenens physicians to extend services and patient access, particularly during peak usage periods,' AMN's Decker said. 'Working alongside nurse practitioners (NPs) and physician assistants (PAs) will also ease their workload and free up their time.' Partnering with NPs was exactly what Ashish Nanda, MD, director of Stroke and Neuro-Interventional at Providence Health System in Orange County, California, proposed to his hospital as he sketched out the creation of a stroke clinic there, which will open in August 2025. 'I realized that our stroke patients were getting discharged but needed follow-up to prevent another one from occurring,' Nanda said. 'The only way to do that was to see them in clinic, so I proposed a dedicated stroke clinic staffed by one specialist and one NP. With two clinicians, we can see more volume and make sure appointments are easier to book.' Another way to boost efficiency is to 'divide and conquer' health conditions within your own practice. 'For example, one partner in the practice can do skin cancer evaluations while the other can focus on complex dermatology procedures,' Spearman said. 'That can be boring for some physicians, but this can really help with scheduling.' This is something Spearman has observed among her ob/gyn colleagues. 'As ob/gyns get older, many are done with the OB life of being on-call,' she said. 'They can opt to focus instead on pelvic disorders or endometriosis. By rethinking how your practice is run, you can streamline the process for patients, too.' Ultimately, the physicians Medscape Medical News spoke with agree that technology will be the ultimate solution to the extensive physician wait times patients are currently experiencing. 'Right now, physicians are spending 50% of their day on administration, whether it's writing notes, following up on labs, and documenting visits, which means they can't see the many patients that need to be seen in a day,' Nanda said. In turn, if AI can cut that administrative time down to 10%, it means a physician can double the number of patients they see, which will ease the current bottleneck, added Samuel R. Browd, MD, PhD, professor of neurological surgery at the University of Washington and attending neurosurgeon at Seattle Children's Hospital in Seattle. 'Our hope is that the emergence of new technology that's clumped under AI is going to create the ability to have more efficiency within the system and allow the current number of providers to be able to scale what they're able to do,' Browd said. 'I'm doing clinic today and probably spend half of the time, if not more, managing Epic, doing paperwork, and documenting visits instead of engaging with patients.' The goal is for AI-powered documentation tools to become more and more of a norm in the hopes that this will help lessen administrative tasks. 'The more burdened we are, the less quality care we can deliver,' Browd said. 'The hope is that with AI and other emerging tools, we can create a better work environment, too.' Happily, Browd says technology is moving rapidly, which may mean that within the next 3-5 years, it will become increasingly easier to make a doctor's appointment — quickly and efficiently. 'If you fast forward to 5 years down the road, what we do day-to-day will be significantly different and will be beneficial in terms of enabling patients to have better access to care,' he said. This will improve the caregiving experience for physicians, too. 'My hope is that this will also change the work environment for doctors in a positive way,' Browd said. 'This will allow us to get back to being doctors, back to the things that brought us into the field in the first place — like taking our time to care for and listen to patients.'
Medscape
31 minutes ago
- Medscape
Can Tumor Patterns Predict Lymphoma Treatment Success?
Large B-cell lymphomas (LBCL) exhibit three distinct microenvironment archetype profiles defined by specific immune and stromal cell patterns. These profiles show divergent cell-cell communication pathways and correlate with different clinical outcomes following CD19 Chimeric Antigen Receptor (CAR) T-cell therapy. METHODOLOGY: Researchers employed single nucleus multiome sequencing of 232 Large B cell lymphoma tumors and controls to comprehensively define the cellular landscape and stereotypical patterns in lymphoma microenvironment archetype profiles. Analysis included 217 lymphomas (110 newly diagnosed and 107 relapsed/refractory cases) and 15 controls. Control tissues comprised nonmalignant reactive lymph nodes biopsied due to suspicion of lymphoma in patients with (n = 13) or without (n = 2) prior lymphoma diagnosis. Available remaining nuclei underwent DNA and RNA extraction followed by whole-exome sequencing (n = 174), low-pass whole-genome sequencing (n = 174), and bulk RNA sequencing (n = 208). TAKEAWAY: Cell subsets co-occurred in three distinct lymphoma microenvironment archetype profiles characterized by: sparsity of T cells with high frequencies of cancer-associated fibroblasts and tumor-associated macrophages; lymph node architectural cell types with naive and memory T cells; or activated macrophages and exhausted CD8+ T cells. Researchers identified that divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets. The Fibroblast/Macrophage archetype showed association with inferior outcomes following first-line rituximab plus chemotherapy treatment. Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease as best response to CD19 CAR T-cell therapy (4/6) compared to Lymph Node archetype (0/8; Fisher test, P = .017). IN PRACTICE: 'The assembly of nonmalignant components of human tumors into prototypical microenvironmental patterns, or archetypes, has been described across cancers. Each archetype consists of a dominant, interconnected cellular network that promotes tumor growth through divergent mechanisms. Furthermore, differences in cell frequency and function between microenvironment archetypes have been suggested as potential biomarkers for immunotherapy response,' the authors of the study wrote. SOURCE: The study was led by Michael Green, PhD, MD Anderson Cancer Center in Houston. It was published online in Cancer Cell . LIMITATIONS: According to the authors, the patient cohort's clinical heterogeneity, while reflecting real-world population, limited their ability to directly assess associations between archetypes and outcomes. The researchers noted that the Fibroblast/Macrophage archetype is linked to high-risk features and increases in prevalence in later therapy lines, while the Lymph Node archetype is associated with low-risk features and declines in prevalence, potentially skewing distribution among treated patients. The authors acknowledged uncertainty about whether LymphoMAPs remain stable between diagnosis and relapse or change with treatment. The researchers emphasized the need for studying LymphoMAP archetypes in uniformly treated cohorts and randomized trials, preferably with biopsies at both baseline and relapse. DISCLOSURES: The study received funding from the Schweitzer Family, the MD Anderson Lymphoid Malignancies Program and NCI P01 CA272295. Michael Green, PhD, reported ties with Sanofi, Kite/Gilead, Abbvie, Allogene, Bristol Myers Squibb, Arvinas, Johnson & Johnson, Daiichi Sankyo, and DAVA Oncology and stock ownership in KDAc Therapeutics. Todd Fehniger, MD, PhD, disclosed being an inventor on patent applications held by Washington University, as well as having relationships with Wugen Inc, Orca Bio, Indapta Therapeutics, HCW Biologics Inc, Affimed, AI Proteins, and the National Institutes of Health. Additional disclosures are noted in the original article.
